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was to collect, in routine clinical practice, data about consequences of switching
from intravenous (IV) EPO to IV DA in patients (pts) with chronic kidney disease
(CKD) receiving dialysis ( 12 months). METHODS: This French monocentre obser-
vational study included adults with CKD receiving dialysis switched from EPO to
DA in July 2010. Data related to EPO and DA dosing and dose frequency, Hb levels,
and iron statuses were collected retrospectively over 36 weeks before the conver-
sion and 36 weeks after the conversion. The primary endpoint estimated the dose
conversion ratio (DCR) between mean EPO doses (UI) and DA (g) during 4 weeks
pre-conversion and 21-24 weeks post-conversion. The mean DCR was determined
with a regression-based method using ordinary least squares (LSQ). RESULTS: A
total of 93 pts were enrolled in this study, (61.3 % female, mean age 70.3 years
(mean time on dialysis 5.2 years). The primary etiologies of CKD were mainly dia-
betes (37.6 %) and hypertension (12.9 %). The arithmetic mean ( SD) EPO dose/
injection at inclusion was 4193  3417 UI with the following injection frequency:
x3/week (44.1 %), x2/week (32.3 %), x1/week (21.5 %) or other (2.1 %). The mean (
SD) DCR on the evaluable population (83 patients, 10 excluded due to missing data)
was 271.3  30.4 (95% CI 264.7, 277.9). The mean ( SD) Hb values were equivalent
over the pre- and post-conversion periods 11.2  0.9 and 11.1  1.0 g/dL, respec-
tively. Iron status was also similar. CONCLUSIONS: In routine clinical practice, the
mean DCR observed in our French dialysis centre, was higher than the factor 200UI:
1g recommended in the DA Summary of Product Characteristics and applied at
switch.
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OBJECTIVES: Kidney transplantation is perceived to be highly cost effective; the
cost of post-transplant management is modest compared to dialysis and quality of
life is significantly improved. While graft survival rates have improved substan-
tially in recent years, on average, graft failure rates are currently 2.9% per annum
across the UK. The objective of this study was to quantify the minimum graft
survival time required for transplantation to remain cost saving compared to
dialysis. METHODS: We utilized a simple decision analytic model with published
input costs for dialysis; immunosuppression and other post-transplant manage-
ment costs were obtained from the PORTRAIT Study (a retrospective observational
study of renal transplant patients) and UK NHS reference costs used for transplan-
tation. We compared the costs of continued dialysis with transplantation and eval-
uated the number of years of functioning graft required for transplantation to
remain cost saving. Future costs were discounted at 3.5%. RESULTS: Over a 10 year
time horizon the total per-patient costs associated with remaining on dialysis was
£394,379; over the same period the total per-patient cost for a functioning graft
were £118,049 representing a saving to the NHS of £276,330 per-patient. Patients
with a 3-year functioning graft prior to returning to dialysis cost an additional
£5,723 compared to remaining on dialysis while 4-year graft survival was cost
saving. CONCLUSIONS: For kidney transplantation to be cost saving recipients
must maintain at least 3 years of functioning graft. In the UK between 3% to 13% of
adult kidney transplants from deceased donors and 2% to 8% from living donors fail
within one year necessitating a return to dialysis. Consequently, a substantial
number of transplant recipients in the UK incur additional and substantial expen-
diture due to poor graft survival rates and, therefore, management strategies to
maximize graft survival should be prioritized in these patients.
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Chronic Kidney Disease (CKD) is the second most frequent complication in 7 mil-
lion diabetes patients in Germany. However, available data on burden of disease is
intransparent. OBJECTIVES: To obtain a comprehensive picture on the conse-
quences of CKD in diabetes patients in Germany from the epidemiological, clinical
and health economics perspective based on available scientific literature.
METHODS: A semi-structured systematic literature review in MEDLINE, CO-
CHRANE, EMBASE and national associations over the last 10 years (2001-2011) and
relevant congress abstracts over the last 2 years. Fields of interest (reviewed sepa-
rately) were epidemiology, health economics, burden of disease and treatment
guidelines with reference to CKD and diabetes. As a conclusion, we conducted a
data gap analysis. RESULTS: Twenty-one epidemiological, 12 burden of disease, 9
health economic full-text articles and 5 treatment guidelines were identified. Prev-
alence of CKD in diabetes patients was 39% but only 0.5% reached dialysis. Acces-
sion rates within all CKD stages were missing. Yearly mortality rates within diabe-
tes patients in dialysis were around 20%. An albumin guideline adherence (albumin
level below 40g/L) could save 23,578 life years. SF-36 was most common generic
HRQoL and KDQoL as disease specific. No data on QoL in pre-dialysis was available.
Highest impairment was physical and emotional functioning. Poor sleep quality
(63%) was significantly associated with higher risk of death (RR1.16, p0.002).
Health care costs were significantly associated with progression of CKD stages.
Direct costs of dialysis were 54,777 €. 60% of dialysis patients lived below the pov-
erty level. CONCLUSIONS: Higher evidence on epidemiological data and disease pro-
gression is desirable. Data within patients in CKD 1-4 was limited or not available. Produc-
tivity lossmighthaveasignificant impactontheburdenofdiseasebutnodatawasfound.
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OBJECTIVES: The number of patients suffering from chronic kidney disease (CKD)
is about 10% of the total world population and 50% of patients with hypertension
and diabetes. About 3400 patients with CKD in Ukraine are treated by hemodialysis.
All these patients need treatment of anemia that associates with CKD by erythro-
poietins (EPs). In Ukraine as well as alfa- and beta-erythropoietins a fundamentally
new product – continuous erythropoietin receptor activator (CERA) are recom-
mended. Its main feature - administration twice a month in treated dose and once
a month in maintenance dose, while others EPs are administrated 2-3 times a
week. The purpose of research is comparative pharmacoeconomic evaluation of
maintenance treatment of anemia in patients with CKD on hemodialysis stage by
different drugs of erythropoietin. METHODS: Decision tree and cost-effectiveness
analysis were used. The costs for EP drugs were determined according to the price
list Pharmacy (2011). The data about equivalent doses of different EPs and their
effectiveness are taken from the results of randomized clinical trials phase III
MAXIMA, PROTOS and RUBRA. RESULTS: Showed that prolonged use of CERA,
which is administrated once a month, effectively maintained stable hemoglobin
level previously is achieved by the administration of shorter-acting EPs (3 times a
week). With appropriate regimen of administration in equivalent doses (according
to the instruction of CERA) the average costs of CERA treatment per patient on
hemodialysis are $173/week (i/v route of administration) and $130/week (s/c route
of administration). The average costs for using the shorter-acting EP drugs are
$267-194/week and $133-182/week respectively. CONCLUSIONS: The use of CERA
in patients with CKD on hemodialysis at the compensative stage instead of shorter-
acting EPs saves about 5-35% of cost for anemia pharmacotherapy. The effective-
ness and safety of therapy do not change.
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OBJECTIVES: Previous research has described treatment failure as discontinuation
of the first anticholinergic or switching in persons with continuous anticholinergic
use. Such research does not account for persons who may restart anticholinergic
use following a period of discontinuation. The objective of this study was to eval-
uate the dynamics of treatment failure in patients with OAB following discontin-
uation of the first anticholinergic.METHODS: Patients in a US commercial database
between January 2005 and June 2010 with  1 filled prescription for an anticholin-
ergic for OAB were included. Treatment failure was defined as patients who dis-
continued therapy (treatment gap of45 days) or switched medications. RESULTS:
There were 182,586 patients who met all inclusion criteria. Treatment failure was
present in a total of 83.4% patients, with 78.3% of patients discontinuing first antich-
olinergic therapy and 5.1% of continued users switching. A total of 30.4% of persons
who discontinued treatment rechallenged after the 45 day treatment gap, with 66.7%
resuming treatment with their original agent. Overall, 54.5% of patients discontinued
anticholinergic treatment permanently within the one year study period. A total of
14.1% of patients switched at least once throughout the study, and patients received
an average of 1.2 (SD: 0.4) unique anticholinergic agents. Of those who initially
switched to a second anticholinergic, 69.6% of patients failed treatment for a second
time either by discontinuing treatment (48.8%) or switching to a third agent (20.8%). A
separate analysis requiring  2 fills found that 85% of patients who switched also
discontinued within the one year study frame. Persons on sustained release anticho-
linergics were less likely to experience treatment failure than those on immediate
release anticholinergics (odds ratio: 0.78 [0.76-0.80], P0.0001).CONCLUSIONS: Treat-
ment failure was high in patients taking anticholinergics for OAB even after taking
restarts into account. Most patients who switched from their first anticholinergic ther-
apy experienced a second treatment failure.
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OBJECTIVES: Kaplan-Meier (KM) curves are commonly used to report time-to-
event outcomes like overall survival (OS) and progression-free survival. For studies
not explicitly reporting hazard ratio (HR) and confidence intervals (CI), KM curves
can be utilised to estimate these summary statistics for conducting a meta-analy-
sis. Here, we validate the method proposed by Parmar and colleagues for estimat-
ing HR (95%CI) by reading the KM curves. METHODS: Ten randomised controlled
trials reporting HR (95%CI) and the associated KM curve for OS were randomly
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selected. Two independent reviewers read the survival probabilities from KM
curves using an open source digitising software (Engauge digitizer). HRs for non-
overlapping time intervals were calculated from the estimated survival probabili-
ties and combined in a stratified way across time intervals to obtain an overall HR
using the spreadsheet by Tierney and colleagues. The estimated HR was compared
with the reported HR for each study. RESULTS: A mean error on the log scale of
0.001 (95%CI: 0.022, 0.019) was observed. This implies that by taking the expo-
nentials, if the reported HR is 0.750, then the estimated HR would be 0.749. The
95%CI for the mean error spans zero indicating any systematic error is likely to be
small and should not influence results in most analytic situations. Mean absolute
error on the log scale was 0.027 (95%CI: 0.016, 0.037) indicating calculated HR lie
within a factor of exponential (0.027) either side of the original value. No change in
the direction of the treatment effect was observed in the estimated HR (95%CI) for
any of the selected study. Reconstructed KM curves presented high accuracy and
reproducibility. CONCLUSIONS: KM curves could be potential source of data and it
is recommended that these should be used more frequently to estimate HR (95%
CI), where not reported explicitly, for conducting meta-analysis in systematic re-
views.
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OBJECTIVES: As more innovative oncology agents become available, budget limi-
tations are necessitating deeper value assessments of products. Previous research
demonstrated that examining a variety of key survival metrics is required to fully
define the value of an anti-neoplastic intervention. Here we examine how various
survival metrics compare across 3 major metastatic tumor types, chosen because
of the introduction of new therapeutics in the past year: melanoma, prostate and
lung cancer. METHODS: We conducted a literature-based review of pivotal clinical
trial data supporting new therapeutics in these tumor types from 2006-2012 and
selected all products with demonstrated overall survival benefit in the metastatic
setting: vemurafinib, ipilimumab for melanoma; cabazitaxel, abiraterone, sipuleu-
cel-T for prostate cancer; pemetrexed, erlotinib, and bevacizumab for lung cancer.
Crizotinib was excluded having not reached median overall survival (OS) at ap-
proval. We compared products on four survival metrics: median OS, mean OS,
1-year survival, and number needed to treat to avoid one event (NNT). RESULTS:
Despite variations in patient tumor types , the products showed a narrow range of
median OS improvement. However, greater variability was seen across other met-
rics: in lung cancer, pemetrexed presented the greater mean OS improvement,
while erlotinib demonstrated greater 1-year survival and lower NNT. In melanoma,
vemurafenib and ipilimumab demonstrated the same number of months of me-
dian OS improvement in their respective clinical trials; however, ipilimumab dem-
onstrated greater mean OS, 1-year survival, and lower NNT. In prostate cancer,
sipuleucel-T demonstrated better mean OS improvement, whereas abiraterone
had better 1-year survival and lower NNT. CONCLUSIONS: Drugs are being evalu-
ated with remarkably similar median OS benefits for metastatic patient popula-
tions. Side-by-side comparisons that take multiple endpoints into account can
assist decison makers to better understand total clinical benefit in context and
contribute to thoughtful resource management, especially when median OS ben-
efit may be so similar.
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OBJECTIVES: Due to pressure to provide rapid access despite uncertainty of a
drug’s real-world value, decision makers often require evidence from outcomes
research. We assessed whether a retrospective observational design can confirm
the trial-based efficacy for the novel agent bortezomib in advanced multiple my-
eloma and identify reasons for any discrepancies. METHODS: Two patient popu-
lations were included: real-world patients in the Netherlands (n72) and the bort-
ezomib pivotal trial population (n333). Data on real-world patients were
retrospectively collected from hospital records (period: 2001-2009). Baseline prog-
nostic factors, treatment patterns, safety and clinical outcomes were compared.
RESULTS: Overall response rates (49% versus 38%; p0.1) and time to progression
(median: 6.8 versus 6.2 months; p0.6) was similar compared to the trial though
the frequency of patient follow-up and definitions used for clinical outcomes var-
ied in daily practice. Overall survival was lower compared to the trial (median: 17.2
versus 29.8 months; p0.01) on account of differences in patient prognosis and use
of the drug. Daily practice patients were more heavily pre-treated in a shorter time
frame at baseline. Practice variation was observed in daily practice with the ma-
jority receiving bortezomib in combination with one or more drugs (68%). Conser-
vative administration was observed with lower cumulative dosages and fewer
treatment cycles (4 versus 6) in daily practice. Safety-related outcomes could not be
compared since this information in patient charts was frequently not detailed.
CONCLUSIONS: A retrospective design confirmed some but not all efficacy end-
points and identified reasons for discrepancies. Evidence generated from retro-
spective studies is complementary to that generated in a trial. Despite threats to
validity of the treatment effect, a retrospective design will generate valuable evi-
dence about who receives the drug and how it is given, which facilitates a feedback
loop to decision makers about ways to improve patient care and ultimately the
drug’s real-world value.
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OBJECTIVES: Immunosuppressive drugs have been subject to different evidence-
based assessments including evaluations along the regulatory process of the EMA
or reimbursement decisions by European HTA agencies. The objective of this re-
search was to review and compare the criteria applied for assessing immunosup-
pressive drugs in renal transplantation. Particular focus was set on the consisten-
cies and differences regarding assessment between the German IQWiG compared
to other European agencies. METHODS: A review of reports and guidelines on
subjects relevant for evidence-based assessment of immunosuppressive therapies
for renal transplantation which were published by EMA, IQWiG, and the European
HTA agencies of France, Scotland, Sweden and UK. The search was restricted to
documents in English or German. RESULTS: We identified relevant documents
from five agencies: one guidance document from EMA, HTA reports from the NICE
in UK, one advice from the SMC in Scotland, assessment summaries from the
French HAS and one report of early benefit assessment from the German IQWiG. No
relevant document was identified from the Swedish SBU. The EMA document pro-
vides guidance for planning of pivotal studies to evaluate safety and efficacy. The
HAS, NICE and SMC appraisals give advice for using immunosuppressive therapies
for renal transplantation and the IQWiG report assessed the additional benefit of
one new immunosuppressant. All documents recommended randomized con-
trolled trials (RCT) or systematic reviews of RCTs as the highest level of evidence.
Differences were in the clinical endpoints considered. In contrast to other agencies
the IQWiG did exclude the endpoints ‘graft function’ and ‘biopsy-confirmed acute
rejection’ from evaluation and did not consider compliance as relevant.
CONCLUSIONS: All agencies consistently recommend a similar standard for the
level of evidence. However, as long as there is no harmonization on the relevant
endpoints considered for evidence-based assessments, the different requirements
of local agencies should be considered when designing clinical trials and planning
statistical analyses.
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OBJECTIVES: According to the social law in Germany the Statutory Health Insur-
ance (GKV) has to address the three dimensions of disease: mortality, morbidity,
and quality of life. Consequently, the recently introduced EBA in Germany is group-
ing the benefits and the related endpoints into these dimensions. Our aim was to
examine the relative importance of each of those dimensions with regards to the
suggested benefit claims by the Institute for Quality and Efficiency in Health Care
(IQWiG). METHODS: The review includes EBAs that were started in 2011. The Joint
Federal Committee’s (GBA) webpage (http://www.g-ba.de/informationen/nutzen-
bewertung/) was used to obtain the respective IQWiG benefit assessments. The
benefit that IQWiG suggested was analysed for each assessment and the attribu-
tion of benefit to each of the three disease domains was examined. RESULTS:
Twenty-four EBAs were started in 2011. Two Orphan indications were excluded
from the analysis (Tafamidis Meglumin, Pirfenidon). In ten EBAs IQWiG suggested
a benefit for the related medication at least in one disease dimension and/or one
subgroup (Telaprevir, Abirateronacetat, Boceprevir, Ipilimumab, Belatacept,
Apixaban, Cabazitaxel, Fingolimod, Ticacrelor, Eribulin). In Abirateronacetat, Ipili-
mumab, Cabazitaxel, Ticacrelor, and Eribulin IQWiG suggested a mortality benefit.
With Ticacrelor IQWiG discriminated overall and cardiovascular mortality. In Tel-
aprevir, Abirateronacetat, Boceprevir, Apixaban, and Ticacrelor IQWiG suggested a
morbidity benefit. Due to the small number of eligible patients Fingolimod was
ultimately not examined regarding morbidity. No benefits were reported in the
dimension of Quality of Life. Side effects that were considered to cause additional
harm to patients and that negatively impacted the overall benefit rating were re-
ported in five EBAs: Boceprevir, Ipilimumab, Apixaban, Cabazitaxel, Eribulin.
CONCLUSIONS: In all reviewed assessments no benefit was attributed to Quality of
Life. The disease dimensions morbidity and mortality were of equal importance.
However, definitions of benefit within the dimension morbidity were very hetero-
geneous across the various EBAs
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OBJECTIVES: UK Pharma considers the UK a leading environment for the conduct
of Real World (RW) health care studies due to the influence of NICE, the cradle-to-
grave health care provided by the NHS, with GPs as the co-ordinators of care for
every patient and the widespread use of e-health records. Is there evidence for this
from research output? We reviewed abstracts published last year at ISPOR as one
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